Penyakit Paru Obstruktif Kronis (PPOK)

01Pathophysiology

COPD is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production) resulting from abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent and often progressive airflow limitation.

The disease begins when chronic inhalation of noxious particles, most commonly cigarette smoke, triggers an amplified inflammatory response in the lung. This inflammatory response is abnormal in both its intensity and its cellular composition. Unlike asthma, which is dominated by eosinophils and CD4+ Th2 lymphocytes, COPD inflammation is driven by neutrophils, macrophages, and CD8+ cytotoxic (Tc1) lymphocytes. Activated macrophages and neutrophils release proteolytic enzymes, notably neutrophil elastase, MMP-8, MMP-9, and MMP-12, that degrade elastin and other structural proteins in the lung parenchyma. This is the "protease" arm of the classic protease-antiprotease imbalance. In a healthy lung, alpha-1 antitrypsin and tissue inhibitors of metalloproteinases (TIMPs) neutralize these enzymes. In COPD, this protective shield is overwhelmed, either by excessive protease release or by a genetic deficiency in alpha-1 antitrypsin (the classic inherited form of emphysema).

Simultaneously, oxidative stress plays a central amplifying role. Cigarette smoke and activated inflammatory cells generate reactive oxygen species that inactivate antiproteases, stimulate mucus hypersecretion, activate pro-inflammatory gene transcription, and reduce histone deacetylase activity, which in turn blunts the anti-inflammatory effect of glucocorticoids. This is why COPD responds poorly to inhaled corticosteroids compared to asthma.

The downstream result of this dual insult is twofold. In the small airways (bronchioles < 2 mm diameter), chronic inflammation causes fibrosis, luminal narrowing, and loss of the alveolar attachments that normally hold these airways open during expiration. This leads to expiratory airflow limitation and air trapping. In the alveolar parenchyma, enzymatic destruction of alveolar walls leads to emphysema, with permanent enlargement of airspaces distal to the terminal bronchiole. The loss of elastic recoil further worsens expiratory flow limitation. Hiperinflation develops as trapped gas increases the functional residual capacity, and this is the primary mechanism behind exertional dyspnea even in early disease.

In the pulmonary vasculature, chronic hypoxia triggers vasoconstriction of small pulmonary arteries, leading to intimal thickening, smooth muscle hypertrophy, and eventually pulmonary hypertension (mPAP > 20 mmHg). Over time, this elevates right ventricular afterload, producing right ventricular hypertrophy and, ultimately, cor pulmonale with right heart failure.

Finally, the systemic inflammatory "spillover" (elevated TNF-alpha, IL-6, CRP) explains the extra-pulmonary manifestations of COPD: skeletal muscle wasting (cachexia), osteoporosis, cardiovascular disease, depression, and metabolic syndrome.

02Classification and Clinical Manifestation

By Severity

All grades require FEV1/FVC < 0.70 after bronchodilator administration.

ABE Group Classification

This ABE grouping replaces the older ABCD system and is the primary tool for guiding initial pharmacotherapy.

Etiotype Classification

Inflammatory Phenotypes

The eosinophilic phenotype is testable because it directly informs the decision of whether to include inhaled corticosteroids in the treatment regimen. A blood eosinophil count >= 300 cells/microL is a strong indication for ICS, while < 100 cells/microL predicts minimal ICS benefit (PPOK PDPI 2023).

03Diagnostic Workup

The diagnosis of COPD is fundamentally a clinical-plus-spirometric diagnosis. The clinical suspicion arises when a patient over 40 years old, with a history of smoking or exposure to biomass fuel, presents with progressive dyspnea, chronic cough, and/or sputum production.

Spirometry is both the best initial test and the gold standard. A post-bronchodilator FEV1/FVC ratio below 0.70 confirms the presence of persistent airflow limitation, which is the defining feature of COPD. In Indonesia, PPOK PDPI 2023 adopts the GOLD criterion of < 0.70. The FEV1 percentage predicted after bronchodilator is then used to grade severity (GOLD 1 through 4).

The bronchodilator reversibility test is performed with 400-800 mcg of inhaled salbutamol; FEV1 is re-measured after 10-15 minutes. An increase of less than 12% and less than 200 mL from baseline indicates poorly reversible obstruction, which characterizes COPD. In contrast, asthma shows robust reversibility. When spirometry is unavailable, peak expiratory flow (PEF) can be used as a surrogate, with a diurnal variability of less than 20% favoring COPD over asthma.

A chest X-ray should be obtained in every patient to exclude alternative diagnoses (tuberculosis, lung cancer, heart failure). In emphysema, the classic radiographic findings are hyperinflation, hyperlucentcy, a widened retrosternal space on the lateral view, flattened diaphragms, widened intercostal spaces, and the "tear drop" or "pendulum" heart silhouette. In chronic bronchitis, the X-ray may appear normal or show increased bronchovascular markings.

HRCT is not required for routine diagnosis but is indicated when the clinical picture does not match the spirometric severity, when lung cancer screening is warranted, or when persistent exacerbations raise suspicion for bronchiectasis. HRCT distinguishes centrilobular emphysema (the predominant pattern in smokers) from panacinar emphysema (alpha-1 antitrypsin deficiency).

Arterial blood gas analysis is critical for evaluating patients with FEV1 < 35% predicted, clinical signs of respiratory failure (cyanosis), or right heart failure. Pulse oximetry with SaO2 < 92% should prompt formal ABG testing.

Blood eosinophil count is an increasingly important biomarker for guiding therapy. Eosinophils >= 300 cells/microL strongly support ICS-containing regimens. Eosinophils < 100 cells/microL indicate minimal benefit from ICS. This test has become a cornerstone of personalized pharmacotherapy in COPD.

04Management and Treatment

Stable COPD

Acute Exacerbation

Smoking Cessation

This is the single most important intervention. It is the only measure proven to slow the decline of FEV1 over time. The Brinkman Index (average cigarettes/day multiplied by years of smoking) or pack-years quantifies the exposure. A structured cessation program should be offered at every visit.

COPD Pharmacotherapy

For Group A (low symptoms, low exacerbation risk): start a single long-acting bronchodilator, either a LABA (e.g., salmeterol 50 mcg DPI twice daily, or indacaterol 150 mcg once daily) or a LAMA (e.g., tiotropium 18 mcg DPI once daily). A short-acting bronchodilator (SABA or SAMA) is used as needed for immediate relief.

For Group B (higher symptoms, low exacerbation risk): a LAMA is preferred as the initial agent. If symptoms persist despite proper inhaler technique and adherence, escalate to a LABA+LAMA combination in a single inhaler (e.g., vilanterol/umeclidinium 25/62.5 mcg once daily, or indacaterol/glycopyrronium 110/50 mcg once daily).

For Group E (high exacerbation risk, regardless of symptom burden): this is where the eosinophil-guided algorithm becomes critical.

• If blood eosinophils < 300 cells/microL: start with LABA+LAMA.

• If blood eosinophils >= 300 cells/microL, or if the patient has a history of asthma overlap: start with LABA+LAMA+ICS triple therapy (e.g., fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg once daily).

• If exacerbations persist on dual bronchodilators despite eosinophils < 100: do NOT add ICS. Instead, add roflumilast (500 mcg orally once daily; indicated when FEV1 < 50% predicted and the patient has a chronic bronchitis phenotype) or add azithromycin (250 mg/day or 500 mg three times weekly for one year, only in former smokers).

ICS should be withdrawn if pneumonia occurs repeatedly or if eosinophils are persistently < 100 cells/microL.

Methylxanthines (theophylline, aminophylline) remain available as adjunctive therapy in Indonesia, but their narrow therapeutic window and risk of toxicity limit their use to settings where other agents are not accessible.

Mucolytics (carbocysteine, NAC, erdosteine) may reduce exacerbation frequency, particularly in patients not receiving ICS.

Non-Pharmacologic Therapy

• Pulmonary rehabilitation: 8-12 weeks of supervised exercise training improves 6-minute walk distance and quality of life (Evidence A). Recommended for Groups B and E.

• Vaccination: influenza (annually), pneumococcal, pertussis, and COVID-19 vaccines are recommended.

• Long-term oxygen therapy: indicated when PaO2 < 60 mmHg (or SaO2 < 88%) at rest on two separate measurements. Target SaO2 during supplementation: 88-92%.

• Nutritional support: malnutrition and cachexia are common and worsen prognosis.

• NIV at home: considered in patients with stable chronic hypercapnic respiratory failure (PaCO2 > 60 mmHg with normal pH).

Acute Exacerbation Management

The three cardinal symptoms of an exacerbation are increased dyspnea, increased sputum volume, and increased sputum purulence.

• Bronchodilators: inhaled SABA (salbutamol 2.5-5 mg via nebulizer every 4-6 hours, or 400-600 mcg via MDI with spacer) is first-line. Add SAMA (ipratropium 0.5-1 mg via nebulizer or 80-120 mcg via MDI every 4-6 hours). When using nebulization, prefer air-driven rather than oxygen-driven nebulizers to avoid worsening hypercapnia. Limit oxygen-driven nebulization to 6 minutes maximum.

• Corticosteroids: prednisone 40 mg orally once daily for 5 days (GOLD recommendation) or 0.5 mg/kg/day for 5 days, extendable to 14 days in very severe exacerbations. IV methylprednisolone is an alternative. High-dose inhaled budesonide (4-8 mg/day in divided doses) has comparable efficacy to IV methylprednisolone.

• Antibiotics: indicated when at least two of three cardinal symptoms are present (one of which must be increased purulence), or when mechanical ventilation is required. Duration: 5-7 days. Initial empiric choices: aminopenicillin +/- clavulanate, macrolide, tetracycline, or fluoroquinolone. Suspect Pseudomonas if the patient has had >= 4 antibiotic courses in the past year, FEV1 < 50%, known bronchiectasis, or prior Pseudomonas culture.

• Oxygen: titrate to SaO2 88-92%. Hyperoxia causes CO2 retention in COPD through loss of hypoxic drive and the Haldane effect.

• NIV: indicated for respiratory acidosis (pH <= 7.35 with PaCO2 >= 45 mmHg), severe dyspnea with signs of respiratory muscle fatigue, or persistent hypoxemia despite supplemental oxygen. Contraindications: respiratory arrest, hemodynamic instability, inability to protect the airway, massive aspiration.

• Invasive mechanical ventilation: indicated when NIV fails, the patient has cardiac or respiratory arrest, severe altered consciousness, or persistent inability to clear secretions.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap on COPD questions is confusing it with asthma based on the presence of wheezing alone. Both diseases cause wheezing and airflow obstruction, but the vignette will plant cues that point you toward COPD: an older patient (>40), a long smoking history, slowly progressive dyspnea (over years, not hours), and airflow limitation that does not fully reverse with bronchodilators. If the stem says "partially reversible" or "poorly reversible" obstruction, that is COPD. If it says "fully reversible," that is asthma. Read for the age, the exposure, and the reversibility.

A second common error involves the oxygen saturation target during an acute exacerbation. Students often default to pushing SaO2 above 95%, but in COPD, the correct target is 88-92%. Hyperoxia suppresses the hypoxic ventilatory drive and worsens CO2 retention. A stem that describes a COPD exacerbation patient who becomes drowsy or confused after high-flow oxygen is testing whether you recognize oxygen-induced hypercapnia.

A third trap involves ICS prescribing. Not all COPD patients benefit from inhaled corticosteroids. The vignette will test whether you know the indications (blood eosinophils >= 300, frequent exacerbations, asthma overlap) and the contraindication signal (recurrent pneumonia, eosinophils < 100). If a COPD patient on ICS develops pneumonia, the next best step is to consider withdrawing ICS, not adding more antibiotics.

Students also commonly miss that the diagnostic criterion is post-bronchodilator FEV1/FVC < 0.70, not pre-bronchodilator. A stem that gives only a pre-bronchodilator ratio is incomplete, and the next step is to perform a bronchodilator reversibility test.

Finally, in Indonesia, be alert for the post-TB obstructive syndrome (SOPT) scenario. A patient with a history of treated TB who has persistent exertional dyspnea, fibrotic/calcified changes on CXR, and irreversible obstruction on spirometry fits this diagnosis, which is classified under COPD and managed with the same bronchodilator-based approach.

The core competency being tested across all COPD questions is the ability to (1) recognize the clinical pattern of a chronic smoker with progressive dyspnea and fixed obstruction, (2) confirm the diagnosis with post-bronchodilator spirometry, (3) classify severity using both spirometric grading and the ABE symptom-exacerbation matrix, and (4) select the correct pharmacotherapy based on the patient's group and eosinophil count.